证券代码：300314 证券简称：戴维医疗 公告编号：2025-032 宁波戴维医疗器械股份有限公司 2024年年度权益分派实施公告 4、本次实施权益分派距离公司股东大会审议通过权益分派方案时间未 超过两个月。 二、权益分派方案 本公司2024年年度权益分派方案为：以公司现有总股本288,000,000 本公司及董事会全体成员保证信息披露的内容真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 宁波戴维医疗器械股份有限公司（以下简称"公司"）2024年年度权 益分派方案已获2025年5月6日召开的2024年度股东大会审议通过，现将权 益分派事宜公告如下： 一、股东大会审议通过利润分配方案情况 1、公司2024年年度股东大会审议通过的2024年年度权益分派方案为： 以截至2024年12月31日公司总股本288,000,000股为基数，向全体股东每10 股派发现金红利0.87元人民币（含税），共计派发现金红利人民币 25,056,000.00元（含税），本次利润分配不送红股，不以资本公积金转增 股本，剩余未分配利润结转以后年度分配。 在分配方案实施前，若公司股本发生变化的，公司将按照"分红总额 不变"的原则 ...

Core Viewpoint - The electric laparoscopic stapler market in China is experiencing growth due to increasing demand for minimally invasive surgeries, despite facing challenges from centralized procurement policies leading to a market size decline in 2024 [1][14]. Overview - Staplers are essential high-value consumables in modern surgery, replacing manual suturing with devices that use titanium staples for tissue connection [2][14]. - The demand for electric laparoscopic staplers is rising as the number of minimally invasive surgeries increases, driven by an aging population and higher expectations for medical service quality [1][14]. Market Policy - The Chinese government has implemented various policies to support the development of the medical device industry, including electric laparoscopic staplers, creating a favorable environment for market growth [6][9]. Industry Chain - The upstream of the electric laparoscopic stapler industry includes suppliers of metals like stainless steel and titanium, as well as polymer materials and components like firing mechanisms and motors [10]. - The midstream involves the research and production of electric laparoscopic staplers, while the downstream focuses on medical institutions that utilize these devices [10]. Development Status - The market for electric laparoscopic staplers is projected to decline to 3.72 billion yuan in 2024, a decrease of 7.38% year-on-year, due to the impact of centralized procurement policies [1][14]. Competitive Landscape - The market for electric laparoscopic staplers in China is relatively stable, with higher entry barriers compared to manual types, and domestic manufacturers are increasingly competing with established international brands [16][19]. - As of May 2025, a total of 210 electric laparoscopic stapler approvals have been granted by the National Medical Products Administration in China [16]. Industry Representative Companies - Jiangsu Fenghe Medical Equipment Co., Ltd. focuses on the development and production of disposable surgical consumables, contributing to advancements in minimally invasive surgery [19]. - Ningbo David Medical Devices Co., Ltd. has a comprehensive product matrix, including electric laparoscopic staplers, and reported a revenue of 5.27 billion yuan in 2024, with 1.887 billion yuan from minimally invasive surgical instruments [21]. Development Trends - Future advancements in electric laparoscopic staplers are expected to integrate sensor and artificial intelligence technologies, enhancing automation and precision in surgical procedures [23].

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of David Medical, indicating a significant decline in revenue and profit in the first quarter of 2025 compared to the previous year [1][2] - As of June 5, 2023, David Medical's stock closed at 12.62 yuan, down 1.48%, with a rolling price-to-earnings (PE) ratio of 87.11 times, and a total market capitalization of 3.635 billion yuan [1] - The company operates in the medical device industry, specifically focusing on obstetric and pediatric care equipment, minimally invasive surgical instruments, and emergency ICU products [1] Group 2 - In the first quarter of 2025, David Medical reported operating revenue of 121 million yuan, a year-on-year decrease of 22.00%, and a net profit of 22.57 million yuan, down 40.78% year-on-year, with a gross profit margin of 57.13% [2] - The average PE ratio for the medical device industry is 50.97 times, with a median of 36.67 times, positioning David Medical at the 102nd rank within the industry [2] - The company has received multiple honors, including recognition as a "Manufacturing Industry Single Champion Cultivation Enterprise" by the Ministry of Industry and Information Technology, and various accolades in Zhejiang Province for its credit management and specialized innovation [1]

6月3日，戴维医疗今日收盘12.77元，上涨2.49%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到88.15倍，创39天以来新低，总市值36.78亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)102戴维医疗88.1564.233.0936.78亿行业平均 50.8049.074.67108.36亿行业中值36.7136.842.4850.19亿1天益医疗-1758.71-3012.481.8822.41亿2澳华内 镜-655.90328.975.2569.12亿3诺唯赞-427.65-505.802.3591.52亿4爱朋医疗-397.87302.264.7932.65亿5博晖 创新-335.73532.763.5849.26亿6奥精医疗-136.87-200.611.8125.40亿7硕世生物-136.24-1990.831.2239.85亿 8睿昂基因-101.37-83.231.4413.12亿9康泰医学-88.33-74.633.1558.14亿10中红医疗-72.73-58.010.9250.55亿 11热景生物-55.61-64.074.10122.37亿 来源： ...

内容概要：随着我国医疗水平的不断提高，越来越多的医疗机构采购婴儿培养箱以满足临床治疗需求， 此外，随着国民生活水平提高，对医疗保健的投入增加，特别是对新生儿护理的重视程度不断提升，愿 意为婴儿培养箱等相关医疗设备支付更高的费用，在此背景下，我国婴儿培养箱市场发展迅速，2024 年，随着一系列医疗器械集中采购政策全面落地实施，对我国婴儿培养箱行业发展产生了深刻的影响， 一方面使婴儿培养箱的需求及接纳程度明显提升，另一方面，受集采降价影响我国婴儿培养箱行业市场 规模有所下滑，据统计，2024年我国婴儿培养箱行业市场规模降至4.15亿元，同比减少4.06%。 上市企业：戴维医疗（300314）、莲池医院（831672.NQ）、华润医疗（01515.HK） 相关企业：深圳市科曼医疗设备有限公司、上海力申科学仪器有限公司、北京巨龙三优科技有限公司、 郑州迪生仪器仪表有限公司、苏州贝茵科技股份有限公司、深圳百生德科技有限公司、山东博科保育科 技股份有限公司 关键词：婴儿培养箱市场政策、婴儿培养箱产业链、汽婴儿培养箱市场规模、婴儿培养箱竞争格局、婴 儿培养箱发展趋势 一、概述 婴儿培养箱控制系统采用计算机技术对箱内温度（箱 ...

证券代码：300314 证券简称：戴维医疗 公告编号：2025-031 本次延续注册的完成，使得公司可以继续生产和销售经皮黄疸仪，对 公司未来经营将产生积极影响。上述产品的实际销售情况取决于未来市场 推广效果，公司目前尚无法预测其对公司未来业绩的影响，敬请投资者注 意投资风险。 特此公告。 宁波戴维医疗器械股份有限公司 董事会 2025年5月30日 宁波戴维医疗器械股份有限公司 关于公司部分医疗器械产品完成延续注册的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 宁波戴维医疗器械股份有限公司（以下简称"公司"）于近日取得由 浙江省药品监督管理局颁发的1项《医疗器械注册证》，公司产品经皮黄 疸仪完成了延续注册，具体如下： | 序号 | 产品名称 | 注册证编号 | 注册证有效期至 | 注册分类 | 适用范围 | | --- | --- | --- | --- | --- | --- | | 1 | 经皮黄疸仪 | 浙械注准 | 2030.11.22 | Ⅱ类 | 用于测量新生儿 | | | | 20202070849 | | | 在光疗前、光疗期 | | ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 证券代码：300314 证券简称：戴维医疗 公告编号：2025-030 宁波戴维医疗器械股份有限公司 关于第一类医疗器械备案信息变更的公告 宁波戴维医疗器械股份有限公司（以下简称"公司"）因生产经 营需要，公司产品医用婴儿床新增了相关型号规格，并于近日取得了 由宁波市市场监督管理局核发的1项《第一类医疗器械备案信息表》， 具体情况如下： 产品名称：医用婴儿床 备案编号：浙甬械备20220083 备案人名称：宁波戴维医疗器械股份有限公司 备案人统一社会信用代码：91330200610257495J 备案人住所：浙江省宁波市象山县石浦科技园区科苑路2号 生产地址：浙江省宁波市象山县石浦科技园区科苑路2号 产品描述：YC-100系列医用婴儿床（以下简称婴儿床）由婴儿盆、 床垫、立柱、储物兜（选配）、储物盆、输液架（选配）和脚轮组成。 产品为无源产品。YC-200系列婴儿床由婴儿盆、支架、床垫、储物筐、 储物兜、储物盆（选配）和脚轮组成。产品为无源产品。 预期用途：用于医疗机构护理、诊疗或转运新生儿、婴儿时使用。 备案日 ...

Core Viewpoint - David Medical's stock closed at 12.4 yuan, down 2.52%, with a rolling PE ratio of 85.59 times, and a total market value of 3.571 billion yuan [1] Company Summary - David Medical specializes in obstetric and pediatric care equipment, minimally invasive surgical instruments, and emergency ICU products, with key products including incubators, radiant warmers, jaundice treatment devices, EEG monitors, and more [1] - As of Q1 2025, two institutions held shares in David Medical, with a total of 1.2529 million shares valued at 0.015 billion yuan [1] - The company has received multiple honors, including recognition as a "Manufacturing Industry Single Champion Cultivation Enterprise" and "AAA Credit Rating Enterprise" [1] Industry Summary - The average PE ratio for the medical device industry is 49.46 times, with a median of 36.16 times, placing David Medical at 102nd in the industry ranking [2] - The company's Q1 2025 performance showed a revenue of 121 million yuan, a year-on-year decrease of 22.00%, and a net profit of 22.5677 million yuan, down 40.78%, with a gross margin of 57.13% [2]

5月14日，戴维医疗今日收盘12.72元，上涨2.33%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到87.80倍，创26天以来新低，总市值36.63亿元。 最新一期业绩显示，2025年一季报，公司实现营业收入1.21亿元，同比-22.00%；净利润2256.77万元， 同比-40.78%，销售毛利率57.13%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)102戴维医疗87.8063.973.0736.63亿行业平均 49.8447.964.65106.43亿行业中值36.6538.442.4547.58亿1天益医疗-1720.32-2946.711.8421.92亿2澳华内 镜-589.71295.774.7262.15亿3诺唯赞-415.01-490.852.2888.81亿4爱朋医疗-368.22279.744.4430.21亿5博晖 创新-326.27517.743.4847.87亿6硕世生物-135.93-1986.301.2239.76亿7奥精医疗-120.78-177.021.5922.41亿 8睿昂基因-97.79-80.291.3912.66亿9康泰医学-85. ...

Group 1: Company Performance - Wens Foodstuff's April chicken sales revenue was 2.543 billion yuan, a year-on-year decrease of 5.01% [1] - Wens Foodstuff sold 10.381 million chickens in April, a year-on-year increase of 10.87% [1] - Wens Foodstuff's average chicken selling price was 11.24 yuan/kg, a year-on-year decrease of 14.91% [1] - Zhongtong Bus's April vehicle sales volume was 1,046 units, a year-on-year decrease of 4.04% [1][2] - Kemin Food's April pig sales revenue reached 70.9048 million yuan, a year-on-year increase of 16.04% [3] - Muyuan Foods sold 6.573 million pigs in April, a year-on-year increase of 51.80% [5] - Muyuan Foods' pig sales revenue was 12.595 billion yuan in April, a year-on-year increase of 53.42% [5] - Xiamen Airport's April passenger throughput was 2.3881 million, a year-on-year increase of 7.73% [24] - Daqin Railway's April cargo transport volume was 30.62 million tons, a year-on-year increase of 0.99% [26] - Shaanxi Coal's April coal production was 14.24 million tons, a year-on-year decrease of 1.78% [28] Group 2: Industry Overview - Wens Foodstuff operates in the agriculture, forestry, animal husbandry, and fishery industry, specifically in pig farming [1] - Zhongtong Bus operates in the automotive industry, focusing on commercial vehicles [2] - Kemin Food operates in the food and beverage industry, specifically in food processing [3] - Muyuan Foods is also in the agriculture, forestry, animal husbandry, and fishery industry, focusing on pig farming [5] - Xiamen Airport is part of the transportation industry, specifically in airport operations [24] - Daqin Railway operates in the coal industry, focusing on coal mining and transportation [26] - Shaanxi Coal is also in the coal industry, focusing on coal mining and related services [28]